NASDAQ:CLNN Clene (CLNN) Stock Price, News & Analysis $2.98 -0.02 (-0.67%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.01 +0.03 (+1.14%) As of 05/2/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Clene Stock (NASDAQ:CLNN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Clene alerts:Sign Up Key Stats Today's Range$2.97▼$3.0550-Day Range$2.58▼$4.5852-Week Range$2.57▼$9.20Volume26,630 shsAverage Volume77,689 shsMarket Capitalization$25.62 millionP/E RatioN/ADividend YieldN/APrice Target$50.20Consensus RatingBuy Company OverviewClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Read More… Clene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreCLNN MarketRank™: Clene scored higher than 50% of companies evaluated by MarketBeat, and ranked 415th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingClene has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClene has only been the subject of 3 research reports in the past 90 days.Read more about Clene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Clene are expected to grow in the coming year, from ($5.19) to ($4.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clene is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clene is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClene has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Clene's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.83% of the float of Clene has been sold short.Short Interest Ratio / Days to CoverClene has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clene has recently decreased by 3.34%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClene does not currently pay a dividend.Dividend GrowthClene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.83% of the float of Clene has been sold short.Short Interest Ratio / Days to CoverClene has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clene has recently decreased by 3.34%, indicating that investor sentiment is improving. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 6 people have searched for CLNN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Clene to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Clene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,932.00 in company stock.Percentage Held by Insiders35.30% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.28% of the stock of Clene is held by institutions.Read more about Clene's insider trading history. Receive CLNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter. Email Address CLNN Stock News HeadlinesClene Inc. (NASDAQ:CLNN) Receives $55.25 Average Price Target from AnalystsApril 26, 2025 | americanbankingnews.comClene initiated with a Buy at JonesResearchApril 24, 2025 | markets.businessinsider.comWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.May 3, 2025 | Stansberry Research (Ad)Jones Trading Initiates Coverage of Clene (CLNN) with Buy RecommendationApril 23, 2025 | msn.comClene to Present at the Emerging Growth ConferenceApril 14, 2025 | globenewswire.comClene announces evidence of remyelination, neuronal repair with CNM-Au8April 8, 2025 | markets.businessinsider.comClene to Present at the Jones Healthcare and Technology Innovation ConferenceApril 1, 2025 | globenewswire.comClene files $160M mixed securities shelfMarch 26, 2025 | markets.businessinsider.comSee More Headlines CLNN Stock Analysis - Frequently Asked Questions How have CLNN shares performed this year? Clene's stock was trading at $5.31 at the beginning of 2025. Since then, CLNN shares have decreased by 43.9% and is now trading at $2.98. View the best growth stocks for 2025 here. How were Clene's earnings last quarter? Clene Inc. (NASDAQ:CLNN) announced its earnings results on Monday, March, 24th. The company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by $0.46. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.13 million. Clene had a negative trailing twelve-month return on equity of 1,106.30% and a negative net margin of 8,556.77%. When did Clene's stock split? Clene's stock reverse split before market open on Thursday, July 11th 2024. The 1-20 reverse split was announced on Thursday, July 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Clene's major shareholders? Clene's top institutional investors include Penn Davis Mcfarland Inc. (0.13%). Insiders that own company stock include General Resonance Llc, David J Matlin, John Henry Stevens, Mark Mortenson, Jonathon Gay, Alison Mosca, Robert Dee Etherington and Robert Glanzman. View institutional ownership trends. How do I buy shares of Clene? Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Clene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clene investors own include Waste Connections (WCN), AUO (AUOTY), Voyager Therapeutics (VYGR), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings3/24/2025Today5/03/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLNN CIK1822791 Webclene.com Phone801-676-9695FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$50.20 High Stock Price Target$84.00 Low Stock Price Target$23.00 Potential Upside/Downside+1,584.6%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,500,000.00 Net Margins-8,556.77% Pretax Margin-8,556.77% Return on Equity-1,106.30% Return on Assets-85.11% Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.82 Sales & Book Value Annual Sales$342,000.00 Price / Sales74.90 Cash FlowN/A Price / Cash FlowN/A Book Value$2.09 per share Price / Book1.43Miscellaneous Outstanding Shares8,596,000Free Float6,236,000Market Cap$25.62 million OptionableOptionable Beta0.46 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CLNN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.